English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  There are several clinical tools that have been developed to predict the likelihood of extended-spectrum β-lactamase producing  Enterobacterales ; however, the creation of these tools included few patients with cancer or otherwise immunosuppressed. The objectives of this retrospective cohort study were to develop a decision tree and traditional risk score to predict ceftriaxone resistance in cancer patients with  Escherichia coli  ( E. coli ) bacteremia as well as to compare the predictive accuracy between the tools.    Methods  Adults age ≥ 18 years old with  E. coli  bacteremia at The University of Texas MD Anderson Cancer Center from 1/2018 to 12/2019 were included. Isolates recovered within 1 week from the same patient were excluded. The decision tree was constructed using classification and regression tree analysis, with a minimum node size of 10. The risk score was created using a multivariable logistic regression model derived by using stepwise variable selection with backward elimination at level 0.2. The decision tree and risk score statistical metrics were compared.    Results  A total of 629  E. coli  isolates were screened, of which 580 isolates met criteria. Ceftriaxone-resistant (CRO-R)  E. coli  accounted for 36% of isolates. The machine learning-derived decision tree included 5 predictors whereas the logistic regression-derived risk score included 7 predictors. The risk score cutoff point of ≥ 5 points demonstrated the most optimized overall classification accuracy. The positive predictive value of the decision tree was higher than that of the risk score (88% vs 74%, respectively), but the area under the receiver operating characteristic curve and model accuracy of the risk score was higher than that of the decision tree (0.85 vs 0.73 and 82% vs 74%, respectively).   Figure 1. Clinical Decision TreeTable 1. Regression Model and Assigned Points for Clinical Risk ScoreTable 2. Statistical Metrics of Clinical Decision Tree and Clinical Risk ScoreConclusion  The decision tree and risk score can be used to determine the likelihood of whether a cancer patient with  E. coli  bacteremia has a CRO-R infection. In both clinical tools, the strongest predictor was a history of CRO-R  E. coli  colonization or infection in the last 6 months. The decision tree was more user-friendly, has fewer variables, and has a better positive predictive value in comparison to the risk score. However, the risk score has a significantly better discrimination and model accuracy than that of the decision tree.    Disclosures    Samuel L. Aitken, PharmD, MPH, BCIDP , Melinta Therapeutoics (Individual(s) Involved: Self): Consultant, Grant/Research Support

open forum infectious diseases

60. Creation and Comparison of a Machine Learning Decision Tree and Traditional Risk Score to Predict Ceftriaxone Resistance in Cancer Patients with <i>E. coli</i> Bacteremia

60. Creation and Comparison of a Machine Learning Decision Tree and Traditional Risk Score to Predict Ceftriaxone Resistance in Cancer Patients with E. coli Bacteremia